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INTRODUCTION
In type 2 diabetes mellitus (T2DM), defective insulin secretion and augmented glucagon secretion contribute to glucose dysregulation [1, 2] . These defects are targeted by the incretin glucagon-like peptide-1 (GLP-1) [3] and, therefore, GLP-1 receptor agonists (GLP-1 RAs) lower glycated hemoglobin (HbA 1c ) [4] . In particular, a reduction in postprandial glucagon secretion by GLP-1 RAs may be of importance for reduced glucose excursion after a meal (postprandial glucose), which is a necessary component of improving glycemic control [5, 6] . However, to what extent postprandial glucagon reductions contribute to the lowering of postprandial glucose excursions in individuals with T2DM is unknown.
Lixisenatide (Lyxumia Ò , Sanofi, Paris, France), a novel GLP-1 RA [7] , has been shown to inhibit glucagon release [8] and to markedly reduce postprandial glucagon in individuals with T2DM [9] . This suggests that a reduction in glucagon may GetGoal-M assessed the efficacy of lixisenatide on glycemic control versus placebo as add-on to metformin, whereas GetGoal-S assessed lixisenatide versus placebo as add-on to sulfonylurea (SU) ± metformin [10, 11] .
METHODS

Overall Study Design
This analysis follows a previously published analysis that investigated the effects of lixisenatide on postprandial glucose, glucagon, and insulin after a meal test [9] . Briefly, a post hoc analysis was performed of pooled data from the modified intent-to-treat populations of two of the lixisenatide Phase 3 trials-GetGoal-M and GetGoal-S.
Inclusion Criteria
As reported previously [10, 11] , GetGoal-M and 
Compliance with Ethics Guidelines
The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
A total of 425 lixisenatide-treated patients and 176 placebo-treated patients had baseline and follow-up assessments for 2-h postprandial glucagon and were included in the analyses. Table 1 .
Glucagon Outcomes
At Week 24, mean (standard error) 2-h postprandial glucagon levels were markedly reduced from baseline in the lixisenatide arm 
DISCUSSION
We showed previously that lixisenatide 20 lg once daily is associated with a significant reduction from baseline to Week 24 in 2-h postprandial glucagon versus placebo in patients with T2DM insufficiently controlled on metformin and/or SU [9] . The novel finding in this current report is that the reduction in postprandial glucagon in lixisenatide-treated patients positively correlates with reduced postprandial glucose and HbA 1c and that this is seen in patients on metformin, as well as SU.
A reduction in postprandial glucagon by lixisenatide has also been reported by Lorenz et al. in patients with T2DM treated with B2 oral glucose-lowering agents [12] and by Meier et al. in patients administering insulin glargine ± metformin [13] . This shows that one of the mechanisms of lixisenatide in T2DM is to reduce postprandial glucagon. The data described herein suggest that this effect may contribute to the lowering of blood glucose concentrations, as demonstrated by the direct positive correlation of 2-h glucagon reductions . Such an effect may be achieved by a reduction in hepatic glucose production by the lowering of glucagon, as it is known that there is a linear relationship between portal glucagon levels and hepatic glucose production [14] . glucagon that is observed with short-term treatment, speculating that long-term benefits may be due to a-cell compensation [15] . The mechanism underlying the reduction in postprandial glucagon by lixisenatide was not established in this post hoc analysis of two Phase 3 studies. Two important mechanisms may, however, be involved. One mechanism is the direct inhibition of glucagon secretion from the islets, which is a well-known effect of GLP-1 [3, 4] , and is also observed with lixisenatide [8] .
Another mechanism is an indirect effect through delayed gastric emptying. A delay in gastric emptying is a well-known effect of lixisenatide [12, 13] and results in diminished nutrient appearance in the circulation, thereby reducing the stimulation of islet function. Such a mechanism may also explain the reduction in 2-h postprandial insulin following lixisenatide administration [9] , as demonstrated previously following exenatide twice-daily treatment [16] . The data described herein contribute to our understanding of how lixisenatide provides glycemic control in patients with T2DM;
however, certain limitations should be acknowledged. First, the populations included in the two studies forming the basis of this post hoc analysis showed some differences in that patients in GetGoal-M had a higher body mass index than those in GetGoal-S, whereas
GetGoal-S included a higher number of patients from Asia and patients with a longer duration of T2DM. Further investigations may address whether this heterogeneity is of importance for treatment with lixisenatide.
Second, the current study does not provide any insight into the relative contribution of lixisenatide in the suppression of gastric emptying or the direct effect of lixisenatide on specific islet cells; this needs to be addressed in future mechanistic studies.
CONCLUSION
In conclusion, this post hoc analysis suggests that the reduction of postprandial glucagon by lixisenatide contributes to reduced postprandial glucose and HbA 1c in patients with T2DM
insufficiently controlled on metformin and/or SU.
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